Tower Research Capital LLC (Trc) Eye Point Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,564 shares of EYPT stock, worth $36,420. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,564
Previous 2,826
61.5%
Holding current value
$36,420
Previous $58,000
32.76%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$66.4 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.3 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$29.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$28.7 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $272M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...